Societal CDMO announced the signing of a master service agreement, MSA, with CivicaScript. This agreement covers an initial project supporting a generic drug candidate that is moving through development and registration efforts, with the potential to expand to include support of additional CivicaScript programs. Under terms of the agreement, Societal CDMO will execute a range of services including analytic method and tech transfer, formulation development, process development, and non-GMP batch manufacturing. “The work that we will conduct under this MSA with CivicaScript provides an excellent opportunity for Societal CDMO to showcase our team’s ability to support the full range of activities required for the development and registration of a generic medicine. We are excited to team up with CivicaScript on this project as we share the company’s commitment to making an impact on the lives of patients. Their dedication to making quality generic medicines affordable and available to everyone fits well with our mission of bringing science to society,” said David Enloe, chief executive officer of Societal CDMO.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SCTL:
- Societal CDMO Signs Master Service Agreement With CivicaScript to Provide CDMO Services
- Societal CDMO management to meet with Craig Halum
- Societal CDMO Enters Agreement With Atossa Therapeutics to Provide Clinical Trial Services (CTS) for Innovative Selective Estrogen Receptor Modulator
- Societal CDMO Reports First Quarter 2023 Financial Results
- Societal CDMO to Participate in RBC Capital Markets Global Healthcare Conference